This content is machine translated Lung cancer Perioperative therapy for better efficacy Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small cell lung cancer (NSCLC). It has now been observed that perioperative therapies can combine the benefits of both…
View Post 4 min This content is machine translated Non-small cell lung cancer The role of adjuvant EGFR TKIs. Over the past several years, tyrosine kinase inhibitors directed against EGFR have gained acceptance as first-line treatment for advanced NSCLC with EGFR mutation. However, their role in adjuvant therapy of…
View Post 5 min This content is machine translated News from the lung cancer pipeline First targeted substance in KRAS mutation and bispecific immunotherapy While targeted therapies in non-small cell lung cancer (NSCLC) have been on the rise for years, such an option for KRAS-mutatedtumors has been lacking. The small molecule inhibitor Sotorasib, which…
View Post 5 min This content is machine translated Non-small cell lung cancer Many lids for many pots In the treatment of non-small cell lung cancer, an extremely large amount has been achieved in a short time. Keeping track of so many rapid innovations can be quite difficult,…
View Post 2 min This content is machine translated Small cell lung carcinoma Regulatory extension for durvalumab Durvalumab was approved EU-wide in combination with chemotherapy of etoposide plus either cisplatin or carboplatin followed by durvalumab maintenance therapy for the first-line treatment of adults with advanced-stage small cell…
View Post 2 min This content is machine translated Small cell lung carcinoma Combined therapy with checkpoint inhibitors is effective Advances in the treatment of small cell lung cancer have been scarce in recent years. Results of second studies now demonstrate a survival advantage for the combination of chemotherapy with…
View Post 14 min This content is machine translated Histological confirmation of lung carcinoma Complex surgery on the lung Drug options in the treatment of lung cancer have developed rapidly in recent years. In addition to classical chemotherapy, immunotherapy and targeted therapy of driver mutations are increasingly coming to…
View Post 4 min This content is machine translated 32nd German Cancer Congress Frontiers of precision medicine in oncology. Targeted therapy, based on molecular characterization of cancer cells, has led to major advances in oncology in recent years. But this is true only for some cancer entities; steel, beam…
View Post 6 min This content is machine translated European Lung Cancer Conference Mutation analysis is crucial for the choice of therapy Three interesting studies were presented at the European Lung Cancer Conference in Geneva. Two were dedicated to the group of NSCLC patients with an EGFR-activating mutation. Can erlotinib neoadjuvant achieve…
View Post 7 min This content is machine translated 8. iron academy Iron deficiency in oncological and renal insufficiency patients. The 8th Iron Academy was not just about iron per se, but put iron deficiency in a larger practical context. Topics included early detection and management of oncology patients and…
View Post 11 min This content is machine translated The focus is often on the quality of life Oncological therapies in elderly patients A geriatric assessment optimizes health status assessment and provides a basis for oncology treatment decisions. Oncological therapies for localized and advanced tumor stages have evolved considerably in recent years, expanding…
